Latest COVID-19 Developments: Cortisone's Mysterious Risk, Children, Vitamin D

Chronic fatigue
According to the latest report from the US Centers for Disease Control and Prevention (US-CDC), more than one-third of people with COVID-19 symptoms who were tested said they had not returned to their normal state of health when researchers called them several weeks after testing.
Scientists have begun studying whether SARS-CoV-2 infection causes postviral problems such as myalgic encephalocele, also known as chronic fatigue.
Several US lawmakers drafted a bill called "Understanding COVID-19 Subsets and the Role of Chronic Fatigue Syndrome with Ensefolmyelitis," which would allocate 60 million Dollars in federal funding for research projects on the long-term effects of COVID-19.
Protecting the next millions
The United States has officially identified COVID-19 cases in more than 5 million people, equivalent to 1.5% of its population. However, if, as research suggests, the actual number of cases is 10 times higher, there is still considerable scope for the virus to spread. Experts are therefore offering advice on addressing the pandemic at this stage and preventing current case numbers from doubling.
In a video interview, Vanderbilt University infectious diseases specialist Dr. William Schaffner said, "My best hope is a vaccine. It must be safe and effective, with a clear, transparent and equitable distribution mechanism that can reach people in the United States and then the whole world.".
Researchers at the University of Washington's Institute for Health Metrics and Evaluation predict that around 300,000 Americans will have died from COVID-19 by December 1 if the country's current tragic situation continues, but estimate that universal mask use would result in 70,000 fewer deaths.
Will the vaccine targets be met?
Moncef Slaoui, head of “Operation Wrap Speed,” the US federal government's initiative to rapidly develop COVID-19 vaccines and treatments, said its previously announced target of distributing 300 million vaccine doses by January 2021 would probably not be fully achieved until the middle of next year, depending on clinical-trial data.
Speaking to the International Committee of Science, Engineering and Medicine, which will publish recommendations on COVID-19 vaccine distribution in September, Dr. Slaoui said the program aims to deliver 300 million doses because some vaccines will probably require two doses.
Slaoui said that, unlike the emergency-use authorizations applied to most COVID-19 diagnostics and treatments released on the US market so far, each vaccine candidate would seek full approval from the US Food and Drug Administration (FDA). He added that Operation Wrap Speed had an agreement with the FDA for rapid data review, but that approval criteria would be the same for every vaccine.
Antibody testing for healthcare workers
SARS-CoV-2 antibody testing among volunteers in New York's healthcare system found positive antibodies in 13.7% of healthcare workers, a frequency slightly higher than that found by other studies among adults statewide.
After accounting for factors such as sex, race and age, researchers found very small differences in the frequency of developing coronavirus antibodies (that is, having had the infection) between people working in settings such as intensive care units and those working at desks.
Glycemic risk of dexamethasone used in critical COVID-19 cases
Although many guidelines address inpatient treatment of hyperglycemia (high blood sugar) associated with dexamethasone (a type of steroid / cortisone), the UK National Diabetes COVID-19 Response Group issued new guidance specifically on blood glucose management in COVID-19 patients receiving dexamethasone.
The authors say this new guidance is needed in view of "dexamethasone-induced impaired glucose metabolism, COVID-19-related insulin resistance and COVID-19-related impaired insulin production".
The issue of volunteering for vaccine studies
More than 32,000 people volunteered to participate in COVID-19 vaccine test trials involving deliberate SARS-CoV-2 exposure, in an effort to accelerate vaccine development and availability.
Bioethicists and doctors are debating an approach that no vaccine trial is currently using. Supporters say challenge tests could shorten vaccine development by months, while others worry that the additional risks could exact a high price in volunteers' health and potentially their lives.
Speaking on August 7, American Medical Association president Dr. Susan Bailey said deliberately exposing people to SARS-CoV-2 (with a weakened-virus vaccine) would be unethical. She added that trials would include healthcare workers, who are exposed to the virus more often than the general public, but that it would take time to see how many people contract the virus during normal life and work to understand how well the vaccine works.
Desperate personal protective equipment (PPE) measures
Small, independent clinics struggled to find enough personal protective equipment during the pandemic, delaying healthcare providers' reopening and putting healthcare workers at risk. Nonprofits and medical associations began stepping in to fill the gap by organizing pooling programs so doctors could buy personal protective equipment orders in bulk.
Medical associations collected members' orders within 1 week, after which nonprofit organizations obtained and distributed the supplies.
AMA president Dr. Bailey said this was not a long-term solution, that they were only trying to fill the current gap, and that they were calling on the administration to do everything possible to increase personal protective equipment production.
Tests: Who should receive them, when and how?
Diagnostic tests for COVID-19 are very important, but it is not yet clear who should receive them, when or how.
Who should be tested? Ideally, everyone should be tested. People who are ill, healthcare workers and known contacts should take priority.
When should testing take place? People with symptoms suggesting COVID-19 should be tested as soon as possible. People with known exposure should be tested around 5 days after exposure, the average incubation period.
How should testing be performed? Only viral nucleic acid or antigen tests should be used to identify acute / current illness.
- Related topic: How Is Coronavirus Testing Performed? What Are PCR and Rapid Diagnostic Test Types?
Fetal pulmonary fibrosis
Danish doctors identified a female patient with COVID-19 who developed Acute Respiratory Distress Syndrome (ARDS) followed by Fetal Pulmonary Fibrosis. Around 42% of patients hospitalized with COVID-19 developed Acute Respiratory Distress Syndrome, which is known to cause pulmonary fibrosis (damage to lung tissue and loss of elasticity).
A London doctor commented: “In practice, doctors caring for COVID-19 patients, particularly those with Acute Respiratory Distress Syndrome, must remain alert to pulmonary fibrosis developing even after mild illness. In patients whose breathlessness persists or worsens weeks or months after acute COVID-19, CT scans should be repeated and lung function monitored.
Rare cases of severe COVID-19 in children
Initial data from the “Critical Coronavirus” and “Pediatric Epidemiology” studies found severe pediatric COVID-19 cases to be rare, with varied symptoms and better outcomes than in adults.
Researchers collected information from 65 pediatric patients treated in intensive care in 18 countries. In a newly published paper, they described initial observations on the first 17 children with severe or critical COVID-19 in 10 pediatric intensive care units in Chile, Colombia, Italy, Spain and the United States.
US National Institute of Health remdesivir clinical-trial update
On Thursday, the National Institute of Health announced the start of a randomized, controlled trial assessing the safety and effectiveness of combining the immune-system regulator "Interferon Beta 1-a" with remdesivir to treat COVID-19 patients. Also known as Adaptive COVID-19 Treatment Trial-3, the study aims to enroll more than 1000 hospitalized COVID-19 patients at around 100 sites worldwide.
All participants will receive standard-dose remdesivir and either interferon beta 1-a or placebo. Researchers will assess whether recovery is faster in the combination-treatment group than in the group receiving remdesivir alone.
FDA revokes emergency-use authorization for a rapid diagnostic test
After granting emergency-use authorization for the Autobio Diagnostics Anti SARS-COV-2 rapid diagnostic test on April 24, the FDA revoked it on August 6, according to a letter from FDA official Dennise M. Hinton.
In her letter, Dennise M. Hilton said the test was unlikely to be effective in detecting SARS-COV-2 Ig-M antibodies and that its known and potential benefits were judged not to outweigh its risks.
Trending clinical topic: Vitamin D
Results of a study published in The FEBS Journal showed that low blood vitamin-D levels were an independent risk factor for COVID-19 infection and hospitalization. These findings generated an idea worth investigating: that people with low vitamin-D levels contract COVID-19 more easily and are therefore hospitalized more often. However, establishing a cause-and-effect relationship is not easy.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.